Results

1–10 of 304 results for Anti-VEGF

Intracameral Delivery of Bevacizumab in the Management of Anterior Segment Recalcitrant Neovascular Complications of Proliferative Vascular Retinopathies
Marib I Akanda, MD
Annual Meeting Talks
2025
Reduced Rates of Diabetic Retinopathy Complications With Use of Continuous Glucose Monitoring: A Multicenter Population-Based Study
Amer F Alsoudi, MD
Annual Meeting Talks
2025
Lower Socioeconomic Status Is Associated With Increased Bevacizumab Use Among Patients Initiating Anti-VEGF Therapy for Diabetic Macular Edema
Judy E. Kim, MD, FASRS
Annual Meeting Talks
2025
Outcomes of Patients With Proliferative Diabetic Retinopathy Treated With Anti-VEGF Therapy and/or PRP in the United States Who Were Lost to Follow-up
Rahul N. Khurana, MD, FASRS
Annual Meeting Talks
2025
Take Out the Trash: Environmental Burden Associated With Intravitreal Injections
Abdullah Abou-Samra, MD
Annual Meeting Talks
2025
Analysis of Antivascular Endothelial Growth Factor Utilization Trends and Prescriber Characteristics Based on Medicare Part B Claims Data: 2017-2022
Stephanie B Engelhard, MD
Annual Meeting Talks
2025
Accuracy of Initial Anti-VEGF Treatment Selection in Newly Diagnosed Neovascular Age-Related Macular Degeneration: Retina Specialist Choice vs Step Therapy
Prithvi Reddy Bomdica, MD, MBA
Annual Meeting Talks
2025
Ixoberogene Soroparvovec (Ixo-vec) Intravitreal Gene Therapy for Neovascular Age-Related Macular Degeneration (nAMD): Results From OPTIC and LUNA Trials
Mark R. Barakat, MD
Annual Meeting Talks
2025
COAST: A Phase 3 Study of Intravitreal Sozinibercept Combined With Aflibercept in Participants With Neovascular Age-Related Macular Degeneration
Charles C Wykoff, MD, PhD, FASRS
Annual Meeting Talks
2025
Vision Outcomes From the DAVIO 2 Trial: A Phase 2 Trial of EYP-1901 vs Aflibercept for Treatment of Neovascular Age-Related Macular Degeneration
Jennifer I. Lim, MD, FARVO, FASRS
Annual Meeting Talks
2025